These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 16461321

  • 1. Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia.
    Claviez A, Eckert C, Seeger K, Schrauder A, Schrappe M, Henze G, von Stackelberg A.
    Haematologica; 2006 Feb; 91(2):272-3. PubMed ID: 16461321
    [Abstract] [Full Text] [Related]

  • 2. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [Abstract] [Full Text] [Related]

  • 3. Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
    Horstmann MA, Hassenpflug WA, zur Stadt U, Escherich G, Janka G, Kabisch H.
    Haematologica; 2005 Dec; 90(12):1701-3. PubMed ID: 16330449
    [Abstract] [Full Text] [Related]

  • 4. Three cases of renal relapse after allogeneic hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia.
    Huck K, Laws HJ, Meisel R, Traeger A, Bernbeck B, Schonberger S, Stackelberg VA, Pape H, Dilloo D.
    Haematologica; 2006 May; 91(5 Suppl):ECR07. PubMed ID: 16709515
    [Abstract] [Full Text] [Related]

  • 5. Early relapse after rituximab chemoimmunotherapy.
    Kiss F, Buslig J, Szegedi I, Scholtz B, Kappelmayer J, Kiss C.
    Pediatr Blood Cancer; 2008 Feb; 50(2):372-5. PubMed ID: 17973316
    [Abstract] [Full Text] [Related]

  • 6. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
    Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero MD, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group).
    Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747
    [Abstract] [Full Text] [Related]

  • 7. Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia.
    Jándula BM, Nomdedeu J, Marín P, Vivancos P.
    Bone Marrow Transplant; 2001 Jan; 27(2):225-7. PubMed ID: 11281397
    [Abstract] [Full Text] [Related]

  • 8. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
    Burkhardt B, Reiter A, Landmann E, Lang P, Lassay L, Dickerhoff R, Lakomek M, Henze G, von Stackelberg A.
    J Clin Oncol; 2009 Jul 10; 27(20):3363-9. PubMed ID: 19433688
    [Abstract] [Full Text] [Related]

  • 9. Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients: a pilot series.
    Chevallier P, Pigneux A, Robillard N, Ayari S, Guillaume T, Delaunay J, Eveillard M, Dumas PY, Lippert E, Mohty M, Leguay T.
    Leuk Res; 2012 Mar 10; 36(3):311-5. PubMed ID: 22172463
    [Abstract] [Full Text] [Related]

  • 10. [Effective combination chemotherapy with rituximab for acute lymphoblastic leukemia with bone relapse after bone marrow transplantation].
    Abe T, Kitajima T, Honma K, Kurasaki T, Okazuka K, Shibasaki Y, Momoi A, Kuroha T, Masuko M, Yagisawa K, Furukawa T, Toba K, Aizawa Y.
    Rinsho Ketsueki; 2008 Nov 10; 49(11):1556-61. PubMed ID: 19047788
    [Abstract] [Full Text] [Related]

  • 11. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
    Aydin S, Dührsen U, Nückel H.
    Ann Hematol; 2007 Apr 10; 86(4):271-6. PubMed ID: 17216473
    [Abstract] [Full Text] [Related]

  • 12. Remission induction with single agent Rituximab in a child with multiply relapsed precursor-B ALL.
    Morris ES, Vora A.
    Br J Haematol; 2007 Oct 10; 139(2):344-5. PubMed ID: 17897313
    [No Abstract] [Full Text] [Related]

  • 13. The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence.
    Attias D, Weitzman S.
    Curr Opin Pediatr; 2008 Feb 10; 20(1):17-22. PubMed ID: 18197034
    [Abstract] [Full Text] [Related]

  • 14. Infusion of anti-CD10 monoclonal antibody (J5) following ablative chemotherapy in a patient with refractory pre-B acute lymphoblastic leukemia.
    Ruiz-Argüelles GJ, Ruiz-Argüelles A, Lobato-Mendizábal E, Presno-Bernal M, Alvarez-Amaya C.
    Rev Invest Clin; 1991 Feb 10; 43(3):259-63. PubMed ID: 1840161
    [Abstract] [Full Text] [Related]

  • 15. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.
    Sebban C, Brice P, Delarue R, Haioun C, Souleau B, Mounier N, Brousse N, Feugier P, Tilly H, Solal-Céligny P, Coiffier B.
    J Clin Oncol; 2008 Jul 20; 26(21):3614-20. PubMed ID: 18559872
    [Abstract] [Full Text] [Related]

  • 16. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA.
    J Clin Oncol; 2008 Jun 20; 26(18):3046-50. PubMed ID: 18565891
    [Abstract] [Full Text] [Related]

  • 17. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
    Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H.
    Cancer; 2006 Apr 01; 106(7):1569-80. PubMed ID: 16502413
    [Abstract] [Full Text] [Related]

  • 18. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
    Al-Ali HK, Wittekind C, Niederwieser D.
    Dtsch Med Wochenschr; 2007 Aug 01; 132(33):1688-91. PubMed ID: 17713864
    [Abstract] [Full Text] [Related]

  • 19. Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma.
    Hess G, Flohr T, Kolbe K, Bonn S, Schuler M, Derigs HG, Huber C.
    Ann Hematol; 2006 Nov 01; 85(11):769-79. PubMed ID: 16896912
    [Abstract] [Full Text] [Related]

  • 20. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
    Harker-Murray PD, Thomas AJ, Wagner JE, Weisdorf D, Luo X, DeFor TE, Verneris MR, Dusenbery KE, MacMillan ML, Tolar J, Baker KS, Orchard PJ.
    Biol Blood Marrow Transplant; 2008 Jun 01; 14(6):685-92. PubMed ID: 18489994
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.